Company · CIK 0001681087 · SIC 2836 — Biological Products, (No Diagnostic Substances) · Nasdaq
Tectonic Therapeutic, Inc. · TECX
Insider activity reported against this company. All insider holders · On EDGAR ↗
Reported at this company — common stock
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 25, 2026 SForm 4 → | Aug 26, 4:30 pm EDT | Peter McNamaraChief Scientific Officer | 43 | $36.52 | $1,570 | 55,285 | −0.08% | 10b5-1 |
| Aug 25, 2026 MForm 4 → | Aug 26, 4:30 pm EDT | Peter McNamaraChief Scientific Officer | 43 | $14.71 | $633 | 55,328 | — | 10b5-1 |
| Aug 12, 2026 SForm 4 → | Aug 14, 7:25 pm EDT | Peter McNamaraChief Scientific Officer | 43 | $35.00 | $1,505 | 55,285 | −0.08% | 10b5-1 |
| Aug 12, 2026 MForm 4 → | Aug 14, 7:25 pm EDT | Peter McNamaraChief Scientific Officer | 43 | $14.71 | $633 | 55,328 | — | 10b5-1 |
| Jun 30, 2026 SForm 4 → | Jul 1, 5:19 pm EDT | Peter McNamaraChief Scientific Officer | 172 | $35.00 | $6,020 | 55,285 | −0.31% | 10b5-1 |
| Jun 30, 2026 MForm 4 → | Jul 1, 5:19 pm EDT | Peter McNamaraChief Scientific Officer | 172 | $14.71 | $2,530 | 55,457 | — | 10b5-1 |
| Jun 20, 2026 FForm 4 → | Jun 23, 5:52 pm EDT | Alise ReicinChief Executive Officer, Director | 924 | $30.34 | $28,034 | 310,623 | — | |
| Jan 16, 2019 JForm 4 → | Jan 18, 5:00 pm EST | SVLSF VI, LLC +310% Owner | 805,323 | — | — | 63,913 | — | plan? |
| Jan 2, 2019 AForm 4 → | Jan 4, 4:28 pm EST | Erik OstrowskiChief Financial Officer | 2,300 | — | — | 2,300 | — | plan? |
| Oct 8, 2018 MForm 4 → | Oct 10, 6:11 pm EDT | Katina DortonChief Financial Officer | 10,000 | $0.91 | $9,100 | 10,000 | — | plan? |
| Oct 8, 2018 MForm 4 → | Oct 10, 6:05 pm EDT | Nerissa KreherChief Medical Officer | 2,942 | $0.91 | $2,677 | 2,942 | — | plan? |
| Jun 25, 2018 CForm 4 → | Jun 25, 6:22 pm EDT | Atlas Venture Fund X, L.P. +210% Owner | 4,756,478 | — | — | 4,756,478 | — | plan? |
| Jun 25, 2018 CForm 4 → | Jun 25, 6:18 pm EDT | Scott RequadtDirector | 2,962,325 | — | — | 2,962,325 | — | plan? |
| Jun 25, 2018 CForm 4 → | Jun 25, 6:16 pm EDT | SVLSF VI, LLC +310% Owner | 2,736,027 | — | — | 90,573 | — | plan? |
| Jun 25, 2018 CForm 4 → | Jun 25, 6:15 pm EDT | Clarus Lifesciences III, L.P. +210% Owner | 2,962,325 | — | — | 2,962,325 | — | plan? |
| Jun 25, 2018 CForm 4 → | Jun 25, 6:15 pm EDT | Bruce BoothDirector | 4,756,478 | — | — | 4,756,478 | — | plan? |
Reported at this company — derivatives (options, RSUs, warrants)
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 3, 2026 AForm 4 → | Sep 8, 4:45 pm EDT | Marc SchwabishChief Business Officer | 17,750 | — | — | 17,750 | — | |
| Sep 3, 2026 AForm 4 → | Sep 8, 4:45 pm EDT | Peter McNamaraChief Scientific Officer | 21,000 | — | — | 21,000 | — | |
| Sep 3, 2026 AForm 4 → | Sep 8, 4:45 pm EDT | Daniel LochnerChief Financial Officer | 24,250 | — | — | 24,250 | — | |
| Sep 3, 2026 AForm 4 → | Sep 8, 4:45 pm EDT | Marcella K. RuddyChief Medical Officer | 24,250 | — | — | 24,250 | — | |
| Sep 3, 2026 AForm 4 → | Sep 8, 4:45 pm EDT | Alise ReicinChief Executive Officer, Director | 69,250 | — | — | 69,250 | — | |
| Aug 25, 2026 MForm 4 → | Aug 26, 4:30 pm EDT | Peter McNamaraChief Scientific Officer | 43 | — | — | 7,787 | — | 10b5-1 |
| Aug 12, 2026 MForm 4 → | Aug 14, 7:25 pm EDT | Peter McNamaraChief Scientific Officer | 43 | — | — | 7,830 | — | 10b5-1 |
| Jun 30, 2026 MForm 4 → | Jul 1, 5:19 pm EDT | Peter McNamaraChief Scientific Officer | 172 | — | — | 7,873 | — | 10b5-1 |
| Jun 11, 2026 AForm 4 → | Jun 12, 4:30 pm EDT | Daniel LochnerChief Financial Officer | 7,500 | — | — | 7,500 | — | |
| Jun 9, 2026 AForm 4 → | Jun 10, 4:45 pm EDT | Timothy A SpringerDirector, 10% Owner | 10,200 | — | — | 10,200 | — | |
| Jun 9, 2026 AForm 4 → | Jun 10, 4:45 pm EDT | Praveen P. TipirneniDirector | 10,200 | — | — | 10,200 | — | |
| Jun 9, 2026 AForm 4 → | Jun 10, 4:45 pm EDT | Phillip B. DonenbergDirector | 10,200 | — | — | 10,200 | — | |
| Jun 9, 2026 AForm 4 → | Jun 10, 4:45 pm EDT | Stefan VitorovicDirector | 10,200 | — | — | 10,200 | — | |
| Jun 8, 2026 AForm 4 → | Jun 10, 4:36 pm EDT | Jessica Caroline ChutterDirector | 20,400 | — | — | 20,400 | — | |
| Mar 5, 2019 AForm 4 → | Mar 7, 4:30 pm EST | Geoffrey MackaySee Remarks, Director | 100,000 | — | — | 100,000 | — | |
| Jan 7, 2019 AForm 4 → | Jan 9, 4:23 pm EST | Philip J. VickersDirector | 18,743 | — | — | 18,743 | — | |
| Jan 2, 2019 AForm 4 → | Jan 4, 4:29 pm EST | Steven AvruchVP & General Counsel | 88,636 | — | — | 88,636 | — | |
| Jan 2, 2019 AForm 4 → | Jan 4, 4:28 pm EST | Erik OstrowskiChief Financial Officer | 186,000 | — | — | 186,000 | — | |
| Dec 17, 2018 AForm 4 → | Dec 19, 5:09 pm EST | Birgitte VolckPresident of R&D | 293,000 | — | — | 293,000 | — | |
| Oct 8, 2018 MForm 4 → | Oct 10, 6:11 pm EDT | Katina DortonChief Financial Officer | 10,000 | — | — | 148,318 | — | |
| Oct 8, 2018 MForm 4 → | Oct 10, 6:05 pm EDT | Nerissa KreherChief Medical Officer | 2,942 | — | — | 24,629 | — | |
| Jun 25, 2018 CForm 4 → | Jun 25, 6:22 pm EDT | Atlas Venture Fund X, L.P. +210% Owner | 19,653,771 | — | — | 0 | — | |
| Jun 25, 2018 CForm 4 → | Jun 25, 6:18 pm EDT | Scott RequadtDirector | 12,240,329 | — | — | 0 | — | |
| Jun 25, 2018 CForm 4 → | Jun 25, 6:16 pm EDT | SVLSF VI, LLC +310% Owner | 11,305,269 | — | — | 0 | — | |
| Jun 25, 2018 CForm 4 → | Jun 25, 6:15 pm EDT | Clarus Lifesciences III, L.P. +210% Owner | 12,240,329 | — | — | 0 | — | |
| Jun 25, 2018 CForm 4 → | Jun 25, 6:15 pm EDT | Bruce BoothDirector | 19,653,771 | — | — | 0 | — | |
| Jun 20, 2018 AForm 4 → | Jun 22, 8:00 pm EDT | Phillip B. DonenbergDirector | 18,743 | — | — | 18,743 | — |